Please login to the form below

Not currently logged in
Email:
Password:

GVAX

This page shows the latest GVAX news and features for those working in and with pharma, biotech and healthcare.

Aduro pancreatic cancer vaccine trial disappoints

Aduro pancreatic cancer vaccine trial disappoints

The immunotherapy combines CRS-207 - a drug that promotes the expression of the tumour-associated antigen mesothelin - with an immune-boosting GVAX cell line, and is Aduro's lead product candidate. ... Aduro is not giving up on the CRS-207/GVAX vaccine

Latest news

  • Pfizer's Bosulif gets conditional green light for CML in Europe Pfizer's Bosulif gets conditional green light for CML in Europe

    mechanism of action than the current crop of treatments, as well as Cephalon/Hospira's Omapro (omacetaxine), BioSante Pharma's GVAX and Deciphera's ABL inhibitor rebastinib (DCC-2036).

  • Combating cancer

    Vaccines such as CancerVax (Canvaxin), Genitope Corp (MyVax personalised immunotherapy), Favrille Inc (FavId), Therion (Panvac), CG 8123 (Gvax; Cell Genesys) have not been as successful, and development of these vaccines has

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Medscape Education Global

Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....